Category - Markets

Markets

Brookline starts Perimeter at buy; PT C$1.54

Brookline Capital Markets initiated coverage of Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) with a “buy” rating and price target of C$1.54 (US$1.11). The stock closed at C$0.32 on July 13. In March 2026...

July 14, 2026

Markets

WB starts Zura Bio at OP; sum-of-the-parts NPV estimate $13.90

William Blair launched coverage of Zura Bio (NASDAQ:ZURA) with an “outperform” rating and sum-of-the-parts NPV estimate of $13.90. The stock closed at $5.08 on July 7. Zura is a clinical-stage, multi-asset immunology...

July 8, 2026

Markets

Rodman & Renshaw starts Atossa at buy; PT $12

Rodman & Renshaw initiated coverage of Atossa Therapeutics (NASDAQ: ATOS) with a “buy” rating and price target of $12.00. The stock closed at $2.28 on July 6. Atossa, a clinical-stage biopharmaceutical company...

July 7, 2026

Markets

Paradigm Capital names Perimeter and maintains Profound as healthcare Top Picks

Paradigm Capital has named Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) as a new Top Pick with a “speculative buy” rating and C$0.95 price target. The stock closed at C$0.275 on July 3. Commenting on the FDA’s...

July 6, 2026

Markets

E.F. Hutton appoints healthcare investment banking veteran Bryan Kobel as managing director

Global investment bank E.F. Hutton & Co. has announced the appointment of former public company CEO Bryan Kobel as managing director. Mr. Kobel rejoins E.F. Hutton, where he previously served as managing director...

June 15, 2026

Markets

Rodman & Renshaw starts Kyntra Bio at buy; PT $30

Rodman & Renshaw initiated coverage of Kyntra Bio (NASDAQ: KYNB) with a “buy” rating and price target of $30.00. The stock closed at $6.63 on June 8. Kyntra Bio (formerly known as FibroGen) is a biopharmaceutical...

June 10, 2026

Markets

Clear Street starts LB Pharmaceuticals at buy; PT $45

Clear Street initiated coverage of LB Pharmaceuticals (NASDAQ: LBRX) with a “buy” rating and price target of $45.00. The stock closed at $28.33 on May 26th. LB Pharmaceuticals is a late-stage biopharmaceutical company...

May 26, 2026

Markets

Tivic rebrands as Valion Bio and changes ticker, closes down 28%

After changing its name from Tivic Health Systems (NASDAQ: TIVC) to Valion Bio (NASDAQ: VBIO), effective at market open today, the company’s stock price declined 28% to close at $1.01, after trading as low as $0.865...

April 28, 2026

Markets

Stifel starts Immunic at buy; PT $2.50

Stifel initiated coverage of Immunic (NASDAQ: IMUX) with a “buy” rating and price target of $2.50. The stock closed at $1.11 on April 15. Immunic is a biotechnology company developing vidofludimus calcium (VidoCa) for...

April 16, 2026

Markets

Rodman & Renshaw starts TuHURA at buy; PT $7

Rodman & Renshaw initiated coverage of TuHURA Biosciences (NASDAQ:HURA) with a “buy” rating and price target of $7.00. The stock closed at $3.15 on April 14th. TuHURA is currently undertaking a Phase 3 trial for its...

April 15, 2026

Category - Markets

Subscribe